A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback